Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.60 |
| ▸ | GHSR | Q92847 | 14/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31505408 | 0.86 | ESR2 (0.56) | NR1H2GHSRSMN1; SMN2ESR2DRD1 | |
| SCHEMBL18617672 | 0.86 | LMNA (0.45) | NR1H2GHSRSMN1; SMN2ESR2POLB | |
| SCHEMBL31505332 | 0.86 | ESR2 (0.56) | NR1H2GHSRSMN1; SMN2ESR2DRD1 | |
| SCHEMBL30645355 | 0.86 | ESR2 (0.56) | NR1H2GHSRSMN1; SMN2ESR2DRD1 | |
| SCHEMBL31505338 | 0.86 | ESR2 (0.56) | NR1H2GHSRSMN1; SMN2ESR2DRD1 | |
| SCHEMBL24528817 | 0.86 | ESR2 (0.56) | NR1H2GHSRSMN1; SMN2ESR2DRD1 | |
| SCHEMBL12280043 | 0.85 | NR1H2 (0.43) | NR1H2GHSRSMN1; SMN2ESR2 | |
| SCHEMBL29676621 | 0.85 | NR1H2 (0.43) | NR1H2GHSRSMN1; SMN2ESR2 | |
| SCHEMBL18586361 | 0.84 | GHSR (0.46) | NR1H2GHSRSMN1; SMN2NPC1POLB | |
| SCHEMBL31532303 | 0.84 | GHSR (0.46) | NR1H2GHSRSMN1; SMN2NPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| WO-2006108709-A1 | 3-SULFONYLAMINO-PYRROLIDINE-2-ONE DERIVATIVES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | TFPI, SERPINC1, SERPINE1 | NR1H2 3160/4885GHSR 2264/4885SMN1; SMN2 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.